Replies to post #4349 on GTC Biotherapeutics (fka GTCB)

[brad toland]

I too have wondered about the manner in which you have raised some questions--not the questions themselves--but at least you have stimulated some interesting discussion on this board.

Regarding sepsis, while indeed sepsis is notorious for many product failures, those attempts were using novel chemical entities--I haven't gone back to look but I'm fairly sure about this-- while in this case Leo is hoping to confirm that by restoring the antithrombin level to a more normal level that the DIC can be stopped. I'm sure it remains a very challenging task because the patients are so compromised by the time DIC gets going. Nonetheless, I remain fairly optimistic that antithtrombin will help significantly based on the Kybersept data, the fact that the study consists relacing an existing blood protein which is abnormally low, and the fact that it is being funded by Leo. I expect Leo didn't decide to try this without some serious thought.

[shears]

Pre_Clinical

I like to see dissenting opinions when backed up and I think you're doing that. I was a long time long on Yahoo's KOSP board and everyone liked me until I said, "OK, we had a nice ride, but I'm taking profits and will sell out soon". I turned into a Pariah, Benedict Arnold, etc. I got accused of a lot of things I didn't deserve. My suggestion is don't take anything personally and stay objective. If you have no hidden agenda beyond what you state (and no alias 'sympathiser') then the truth will become evident.

On the other hand, if you are someone who is heavily invested in an alternative therapeutic protein production platform with a hidden agenda to discredit GTCB and scare off other investors then you are truly wasting your time.

Have a great day.